MYLAN PUERTO RICO MANUFACTURING PLANT
MYLAN PUERTO RICO MANUFACTURING PLANT is expected "to become operational in approximately 12 months": the tax/profit benefits should begin accruing to Mylan "during the third and fourth quarters of [the company's] fiscal year ending March 31, 1988." Mylan announced plans for the new facility as part of groundbreaking ceremonies on Oct. 8. The firm is building a 50,000 square foot pharmacuetical manufacturing plant on ten acres of land in Caguas, Puerto Rico, 20 miles south of San Juan. Mylan is at least the third generic firm to take advantage of tax benefits through Puerto Rican operations. Bolar built a 22,000 square foot plant in Humacao, Puerto Rico, in 1984, which was expanded an additional 32,000 square feet in 1985 ("The Pink Sheet" Feb. 24, 1985, In Brief). In January, Zenith announced plans to expand its manufacturing facilities in Cidra, Puerto Rico through the acquisition of a 70,000 square foot plant ("The Pink Sheet" Jan. 20, T&G-2). Mylan noted that the new Puerto Rican plant will cost between $7 and $8 mil. The product line for Puerto Rican production has not been set, Mylan said. The plant will be equipped to manufacture both tablet and capsule products.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth